Jose David, MD
Family Medicine · Albany, NYNPI 1831181981
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $61,918 of the $102,828 with a category attached, or 60.2%. 60 manufacturers reported payments, led by AbbVie at 35.5% of the total. Among family medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,593 payments — averaging $64.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$37K
- Johnson & Johnson$29K
- Idorsia Pharmaceuticals US Inc$11K
- AstraZeneca$3K
- Sanofi-aventis U.S. LLC$2K
- Novo Nordisk$2K
- plus $19K from 54 others
Across 1 payment — averaging $2750.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Renalytix AI, Inc.$3K
What the payments were for
- Consulting fees$2,0652%
- Speaking & faculty fees$61,91860%
- Travel & lodging$5,0325%
- Food & beverage$33,29432%
- Education$5201%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$102,828 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 519 | $304,733 |
| SpravatoEsketamine Hcl | 164 | $217,921 |
| JardianceEmpagliflozin | 239 | $201,581 |
| RybelsusSemaglutide | 149 | $177,881 |
| RexultiBrexpiprazole | 82 | $127,912 |
| FarxigaDapagliflozin Propanediol | 136 | $121,692 |
| OzempicSemaglutide | 89 | $103,734 |
| JanuviaSitagliptin Phosphate | 105 | $94,168 |
| AustedoDeutetrabenazine | 16 | $90,095 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 118 | $82,728 |
| MounjaroTirzepatide | 69 | $75,066 |
| Tresiba Flextouch U-100Insulin Degludec | 66 | $64,428 |
| TrulicityDulaglutide | 29 | $64,204 |
| TradjentaLinagliptin | 56 | $51,430 |
| OtezlaApremilast | 14 | $46,148 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic, Wegovy | $1,710 | $312,772262 claims |
| PfizerEliquis | $784 | $304,733519 claims |
| Boehringer IngelheimJardiance, Tradjenta | $310 | $253,010295 claims |
| Johnson & JohnsonSpravato, Xarelto | $28,799 | $247,966193 claims |
| Lilly USA, LLCMounjaro, Trulicity, Olanzapine | $1,308 | $153,374362 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $2,709 | $143,928171 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $420 | $127,91282 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $745 | $120,653203 claims |
| MerckJanuvia | $382 | $94,168105 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $446 | $90,09516 claims |
| AmgenOtezla, Prolia | $925 | $68,26927 claims |
| NovartisEntresto | $264 | $34,79748 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.
Other family medicine in Albany
- Daniel ArenosAlbany$25K
- Louis BonavitaEast Syracuse$674K
- Martin MahoneyBuffalo$520K
- Scott BrehautClinton$514K
- David St PeterSaratoga Springs$395K
- Matthew PabisNew York$222K
- Rajveer SachdevPomona$211K
- Eric SchnakenbergHalfmoon$190K
- James NorthGlens Falls$186K
- Eric BatesNew York$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.